Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.752,38
1,37%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Quince Therapeutics Inc (QNCX) Quince Therapeutics Inc (QNCX) Notizie

Quince Therapeutics Inc

QNCX
0,9851
0,0251 (2,61%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/4/202413:00BWQuince Therapeutics Provides Business Update and Reports..
22/2/202413:00BWQuince Therapeutics Launches Scientific Advisory Board
15/2/202422:00EDGAR2Form 8-K - Current report
15/2/202413:00BWQuince Therapeutics Appoints Former Reata Pharmaceuticals..
07/2/202422:05BWQuince Therapeutics to Present at Oppenheimer 34th Annual..
02/2/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:01EDGAR2Form 8-K/A - Current report: [Amend]
04/1/202422:05BWQuince Therapeutics to Participate at Investor Events in..
03/1/202422:02EDGAR2Form 8-K - Current report
22/12/202322:08EDGAR2Form 8-K - Current report
15/12/202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:06EDGAR2Form 8-K - Current report
08/12/202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202319:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202323:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202301:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202301:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/10/202322:05EDGAR2Form 8-K - Current report
23/10/202313:00BWQuince Therapeutics Completes Acquisition of EryDel S.p.A.
28/9/202322:53DJNQuince Therapeutics to Advance Study of EryDex as FDA Lifts..
28/9/202322:05BWU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s..
06/9/202313:18EDGAR2Form 8-K - Current report
06/9/202313:00BWQuince Therapeutics Appoints Dr. Charles S. Ryan as..
01/9/202300:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202300:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202323:05EDGAR2Form 8-K - Current report
10/8/202322:05BWQuince Therapeutics to Present at Sidoti Virtual Investor..
10/8/202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202300:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202323:56BWQuince Therapeutics rileva EryDel SpA e il suo asset di fase..
24/7/202313:16EDGAR2Form 8-K - Current report
24/7/202313:00BWQuince Therapeutics to Acquire EryDel SpA and its Phase 3..
Apertura: 0,92 Min: 0,92 Max: 0,99
Chiusura: 0,96

La tua Cronologia

NASDAQ
QNCX
Quince Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network